Send to

Choose Destination
J Prev Alzheimers Dis. 2018;5(1):26-30. doi: 10.14283/jpad.2017.23.

Effects of Omega-3 Fatty Acids on Resting Cerebral Perfusion in Patients with Mild Cognitive Impairment: A Randomized Controlled Trial.

Author information

Claudia Schwarz, MSc, Charité - Universitätsmedizin Berlin, NeuroCure Clinical Research Center NCRC, Charitéplatz 1, D-10117 Berlin, E-mail:, Phone: + 49-30-450-660395, Fax: + 49-30-450-7560280.


Alteration of cerebral perfusion can be considered as a possible therapeutic target in mild cognitive impairment. This randomized, placebo-controlled, double-blind proof-of-concept study assessed effects of omega-3 fatty acids on cerebral perfusion in patients with mild cognitive impairment. In thirteen patients (omega:n=5; placebo:n=8) cerebral perfusion was measured before and after 26-weeks intervention within posterior cortical regions using magnetic resonance imaging. There was a medium effect of intervention on cerebral blood flow (η2=0.122) and blood volume (η2=0.098). The omega group showed an increase in blood flow (mean difference: 0.02 [corresponds to 26.1%], 95% confidence interval:0.00-0.05) and blood volume (mean difference: 0.08 [corresponds to 18.5%], 95% confidence interval:0.01-0.15), which was not observed in the placebo group. These preliminary findings suggest that omega-3 fatty acids supplementation may improve perfusion in cerebral regions typically affected in mild cognitive impairment.Regulation of perfusion may help to maintain brain structure and function and potentially delay conversion to dementia.


Alzheimer’s disease prevention; Omega-3 fatty acids; cerebral perfusion; dynamic susceptibility contrast magnetic resonance imaging; mild cognitive impairment


Conflict of interest statement

Claudia Schwarz has nothing to disclose. Dr. Miranka Wirth has nothing to disclose. Dr. Lea Gerischer has nothing to disclose. Dr. Ulrike Grittner has nothing to disclose. Dr. Theresa Köbe has nothing to disclose. Dr. A. Veronica Witte has nothing to disclose. Prof. Dr. Agnes Flöel has obtained consulting fees from Schwabe, Honoraria for oral presentations from Novartis, Böhringer-Ingelheim, Schwabe, and Souvenaid, as well as royalties from the book ‘‘Alzheimer-Unabwendbares Schicksal?’.

Supplemental Content

Loading ...
Support Center